Yeo details the use of PBPK modeling alongside organ-on-a-chip technology to predict fetal drug exposure and optimize the maternal risk-benefit ratio.
Karen Yeo, PhD
Advertisement
Karen Yeo, PhD, Senior vice president, Client & Regulatory Strategy, Certara UK
Articles by Karen Yeo, PhD
According to Karen Yeo, PhD, the use of 100 to 200 PBPK models is moving drug administration toward a more personalized, informed decision-making process for pregnant women.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
CMS' obstetric G-codes cause confusion, perimenopause uncertainty, Zuranolone real-world data
2
CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition
3
CDC: 15% of US women report drinking alcohol during pregnancy
4
National strategy calls for $20B investment to close women's health gap
5